Publications by authors named "B Druker"

Claim this Profile
T
The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor.
Jennifer N Saultz, Daniel Bottomly, Faith Burns, Kaelan Byrd, Yoko Kosaka, Brian J Druker

Front Immunol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.
Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T Swords, Elie Traer, Brian J Druker

Haematologica· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.
Eric D Eisenmann, Ronan Swords, Ying Huang, Shelley Orwick, Daelynn Buelow, Brian J Druker

Cancer Res Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib.
Serena Muratcioglu, Christopher A Eide, Chien-Lun Hung, Kent Gorday, Emily Sumpena, Brian J Druker

Sci Signal· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying Drug Combination Strategies for Fusion Positive Leukemia.
Ariane Huang, Sofia R Beer, Christopher A Eide, Brian J Druker, Jeffrey W Tyner

Precis Oncogenom· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis